MRNA Jan 2024 260.000 call
| Previous close | 0.0500 |
| Open | 0.0500 |
| Bid | 0.0200 |
| Ask | 0.0600 |
| Strike | 260.00 |
| Expiry date | 2024-01-19 |
| Day's range | 0.0500 - 0.0500 |
| Contract range | N/A |
| Volume | |
| Open interest | 1.51k |
Motley FoolHere's Why You Should Consider Moderna Stock, and No, It's Not the COVID Vaccine
Once a relatively unknown biotech company, Moderna (NASDAQ: MRNA) became a household name when it became one of the first companies to offer a vaccine for the COVID-19 virus. At its peak, Moderna saw quarterly revenue of $7 billion as it sold vaccines to the world. Its stock price followed suit, reaching an all-time high of $484 in mid-2021.
Motley FoolIf I Could Only Buy 3 Stocks in 2023, I'd Pick These
CRISPR Therapeutics (NASDAQ: CRSP) specializes in gene editing, or the repair of faulty genes responsible for disease. Right now, CRISPR is heading for its biggest moment ever -- a regulatory decision on what may become its first commercialized product. The U.S. Food and Drug Administration (FDA) is set to decide on exa-cel for sickle cell disease in December and on exa-cel for beta thalassemia in March.
ZacksIs it Time to Buy Pfizer, Moderna, or AstraZeneca's Stock?
Despite slowing COVID-19 vaccine sales these healthcare titans are trading at more reasonable valuations with a lot of the risk-to-reward being priced into their stocks considering their earnings potential.
